These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 37379881)

  • 1. Rapid development of cefiderocol resistance in a carbapenem-resistant Pseudomonas aeruginosa isolate associated with mutations in the pyoverdine biosynthesis pathway.
    Brakert L; Berneking L; Both A; Berinson B; Huang J; Aepfelbacher M; Wolschke C; Wichmann D; Rohde H
    J Glob Antimicrob Resist; 2023 Sep; 34():59-62. PubMed ID: 37379881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Siderophores promote cooperative interspecies and intraspecies cross-protection against antibiotics in vitro.
    Galdino ACM; Vaillancourt M; Celedonio D; Huse K; Doi Y; Lee JS; Jorth P
    Nat Microbiol; 2024 Mar; 9(3):631-646. PubMed ID: 38409256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of carbapenem-resistant
    Canton R; Doi Y; Simner PJ
    Expert Rev Anti Infect Ther; 2022 Aug; 20(8):1077-1094. PubMed ID: 35502603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of Cefiderocol Against
    Iregui A; Khan Z; Landman D; Quale J
    Microb Drug Resist; 2020 Jul; 26(7):722-726. PubMed ID: 32031915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of the novel siderophore cephalosporin, cefiderocol, in Gram-negative pathogens in Europe by site of infection.
    Candel FJ; Santerre Henriksen A; Longshaw C; Yamano Y; Oliver A
    Clin Microbiol Infect; 2022 Mar; 28(3):447.e1-447.e6. PubMed ID: 34298176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolution of Cefiderocol Non-Susceptibility in Pseudomonas aeruginosa in a Patient Without Previous Exposure to the Antibiotic.
    Streling AP; Al Obaidi MM; Lainhart WD; Zangeneh T; Khan A; Dinh AQ; Hanson B; Arias CA; Miller WR
    Clin Infect Dis; 2021 Dec; 73(11):e4472-e4474. PubMed ID: 33411899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cefiderocol resistance genomics in sequential chronic Pseudomonas aeruginosa isolates from cystic fibrosis patients.
    López-Causapé C; Maruri-Aransolo A; Gomis-Font MA; Penev I; Castillo MG; Mulet X; de Dios Caballero J; Campo RD; Cantón R; Oliver A
    Clin Microbiol Infect; 2023 Apr; 29(4):538.e7-538.e13. PubMed ID: 36435424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.
    Bassetti M; Echols R; Matsunaga Y; Ariyasu M; Doi Y; Ferrer R; Lodise TP; Naas T; Niki Y; Paterson DL; Portsmouth S; Torre-Cisneros J; Toyoizumi K; Wunderink RG; Nagata TD
    Lancet Infect Dis; 2021 Feb; 21(2):226-240. PubMed ID: 33058795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies of Pseudomonas aeruginosa Mutants Indicate Pyoverdine as the Central Factor in Inhibition of Aspergillus fumigatus Biofilm.
    Sass G; Nazik H; Penner J; Shah H; Ansari SR; Clemons KV; Groleau MC; Dietl AM; Visca P; Haas H; Déziel E; Stevens DA
    J Bacteriol; 2018 Jan; 200(1):. PubMed ID: 29038255
    [No Abstract]   [Full Text] [Related]  

  • 11. Cefiderocol for treatment of an empyema due to extensively drug-resistant
    Kufel WD; Steele JM; Riddell SW; Jones Z; Shakeraneh P; Endy TP
    IDCases; 2020; 21():e00863. PubMed ID: 32577400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of cefiderocol against clinically important carbapenem non-susceptible Gram-negative bacteria from Saudi Arabia.
    Alzayer M; Alghoribi MF; Alalwan B; Alreheli A; Aljohani S; Bosaeed M; Doumith M
    J Glob Antimicrob Resist; 2023 Mar; 32():176-180. PubMed ID: 36481491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of carbapenem-resistant Pseudomonas aeruginosa clinical isolates, carrying multiple genes coding for this antibiotic resistance.
    Rizek C; Fu L; Dos Santos LC; Leite G; Ramos J; Rossi F; Guimaraes T; Levin AS; Costa SF
    Ann Clin Microbiol Antimicrob; 2014 Sep; 13():43. PubMed ID: 25179208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia.
    Delgado-Valverde M; Conejo MDC; Serrano L; Fernández-Cuenca F; Pascual Á
    J Antimicrob Chemother; 2020 Jul; 75(7):1840-1849. PubMed ID: 32277821
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Nakamura R; Ito-Horiyama T; Takemura M; Toba S; Matsumoto S; Ikehara T; Tsuji M; Sato T; Yamano Y
    Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31262762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid Development of Cefiderocol Resistance in Carbapenem-resistant Enterobacter cloacae During Therapy Is Associated With Heterogeneous Mutations in the Catecholate Siderophore Receptor cirA.
    Klein S; Boutin S; Kocer K; Fiedler MO; Störzinger D; Weigand MA; Tan B; Richter D; Rupp C; Mieth M; Mehrabi A; Hackert T; Zimmermann S; Heeg K; Nurjadi D
    Clin Infect Dis; 2022 Mar; 74(5):905-908. PubMed ID: 34079986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Compassionate Use of Cefiderocol in the Treatment of an Intraabdominal Infection Due to Multidrug-Resistant Pseudomonas aeruginosa: A Case Report.
    Stevens RW; Clancy M
    Pharmacotherapy; 2019 Nov; 39(11):1113-1118. PubMed ID: 31550054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective role of cefiderocol in the management of carbapenem-resistant Acinetobacter baumannii infections: Review of the evidence.
    Kollef M; Dupont H; Greenberg DE; Viale P; Echols R; Yamano Y; Nicolau DP
    Int J Antimicrob Agents; 2023 Aug; 62(2):106882. PubMed ID: 37301312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Siderophore Cephalosporin Cefiderocol Utilizes Ferric Iron Transporter Systems for Antibacterial Activity against Pseudomonas aeruginosa.
    Ito A; Nishikawa T; Matsumoto S; Yoshizawa H; Sato T; Nakamura R; Tsuji M; Yamano Y
    Antimicrob Agents Chemother; 2016 Dec; 60(12):7396-7401. PubMed ID: 27736756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stability and low induction propensity of cefiderocol against chromosomal AmpC β-lactamases of Pseudomonas aeruginosa and Enterobacter cloacae.
    Ito A; Nishikawa T; Ota M; Ito-Horiyama T; Ishibashi N; Sato T; Tsuji M; Yamano Y
    J Antimicrob Chemother; 2018 Nov; 73(11):3049-3052. PubMed ID: 30188999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.